Clinical relevance of sST2 in cardiac diseases

Pascual Figal, Domingo A.; Lax, Antonio; Perez Martinez, Maria T.; Asensio Lopez, Maria del Carmen; Sanchez Mas, Jesus; Lax Pérez, Antonio Manuel

Publication:
Clinical relevance of sST2 in cardiac diseases

dc.contributor.author	Pascual Figal, Domingo A.
dc.contributor.author	Lax, Antonio
dc.contributor.author	Perez Martinez, Maria T.
dc.contributor.author	Asensio Lopez, Maria del Carmen
dc.contributor.author	Sanchez Mas, Jesus
dc.contributor.author	Lax Pérez, Antonio Manuel
dc.contributor.department	Medicina
dc.date.accessioned	2024-01-22T17:11:36Z
dc.date.available	2024-01-22T17:11:36Z
dc.date.issued	2015-05-09
dc.description	©2015. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ This document is the Published, version of a Published Work that appeared in final form in Clinical Chemistry and Laboratory Medicine (CCLM). To access the final edited and published work see https://doi.org/10.1515/cclm-2015-0074	es
dc.description.abstract	ST2 has two main isoforms, ST2L and soluble isoform of ST2 (sST2), by alternative splicing. The interaction between interleukin (IL)-33 and the transmembrane isoform ST2L is up-regulated in response to myocardial stress and exerts cardio-protective actions in the myocardium by reducing fibrosis, hypertrophy and enhancing survival. The circulating isoform sST2, by sequestering IL-33, abrogates these favorable actions and will be elevated as a maladaptive response to cardiac diseases. Indeed, circulating sST2 concentrations correlate with a worse phenotype of disease including adverse remodeling and fibrosis, cardiac dysfunction, impaired hemodynamics and higher risk of progression. In patients with acute and chronic heart failure, sST2 concentrations are strongly predictive of death, regardless of the cause and left ventricle (LV) ejection fraction, and contribute relevant information in addition to other prognosticators and biomarkers, as natriuretic peptides or troponins. sST2 also retains prognostic information in the setting of acute myocardial infarction (AMI) and predicts cardiovascular death and risk of heart failure (HF) development in these patients. sST2 could also be a promising tool to stratify the risk of sudden cardiac death (SCD) in patients with depressed LV ejection fraction. Therefore, sST2 represents a clinically relevant biomarker reflecting pathophysiological processes and contributing predictive information in the setting of several cardiovascular diseases, and especially in patients with HF.	es
dc.format	application/pdf	es
dc.format.extent	7	es
dc.identifier.citation	Clinical Chemistry and Laboratory Medicine (CCLM)
dc.identifier.doi	https://doi.org/10.1515/cclm-2015-0074
dc.identifier.issn	1437-4331
dc.identifier.issn	1434-6621
dc.identifier.uri	http://hdl.handle.net/10201/137528
dc.language	eng	es
dc.relation	This work was supported by a grant from “Instituto de Salud Carlos III” PI14/01637	es
dc.rights	info:eu-repo/semantics/openAccess	es
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject	Biomarkers	es
dc.subject	Coronary disease	es
dc.subject	Heart failure	es
dc.subject	ST2	es
dc.title	Clinical relevance of sST2 in cardiac diseases	es
dc.type	info:eu-repo/semantics/article	es
dspace.entity.type	Publication	es